Robert Hendel, MD
Cardiovascular Disease · New Orleans, LANPI 1790738862
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,865 of the $9,929 with a category attached, or 79.2%. Astellas Pharma US Inc accounts for 90.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $9,174 and has fallen 96.9% since, to $287 in 2025.
Across 18 payments — averaging $551.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$9K
- Alnylam Pharmaceuticals Inc.$252
- GE HealthCare$199
- Pfizer$197
- Biotronik Inc.$135
- Medtronic$122
- plus $83 from 2 others
Across 5 payments — averaging $5211.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$26K
What the payments were for
- Speaking & faculty fees$7,86579%
- Travel & lodging$8759%
- Food & beverage$1,18912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 6 | $8,941 |
| Alnylam Pharmaceuticals Inc. | 2 | $252 |
| GE HealthCare | 2 | $199 |
| Pfizer | 4 | $197 |
| Biotronik Inc. | 1 | $135 |
| Medtronic | 1 | $122 |
| Jubilant Draximage Inc. | 1 | $69 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LEXISCAN$3,676
- ONPATTRO$252
- Orsiro Mission$135
- PK Papyrus$135
- CoreValve Evolut$122
- VYNDAMAX$101
How this compares
$9,929 in reported general payments places this provider in the 75th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 16 | $20,643 |
| Clonidine | 12 | $1,754 |
| Metoprolol Succinate | 49 | $657 |
| Atorvastatin Calcium | 55 | $642 |
| Minoxidil | 15 | $338 |
| Spironolactone | 41 | $189 |
| Lisinopril | 21 | $182 |
| Furosemide | 25 | $123 |
| Amlodipine Besylate | 31 | $114 |
| Hydrochlorothiazide | 27 | $97 |
| Losartan Potassium | 18 | $87 |
| Carvedilol | 16 | $87 |
| Ezetimibe | 18 | $62 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.